TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of intrapartum Cesarean Section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients wishing to participate in research
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum AMH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Variation in Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Block sensory level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of osteomyelitis recurrence or new osteomyelitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Bilateral Coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed agility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression levels as measured by the Taiwanese Depression Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety levels as measured by the Hospital Anxiety and Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parenting Sense of Competency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parent-Infant Interaction
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Number of participants in normal sinus rhythm (NSR) by ECG after DCCV shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and severity of Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of grade 2 or 3 bone pain
Endpoint domain: Adverse events/effects
Primary endpoint: Investigator's Global Assessment - Facial Wrinkle Severity (IGA-FWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Investigator's Global Assessment - Facial Hyperpigmentation and Wrinkle Severity (IGA-FHWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Caloric and protein gap
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of the operation measured by adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Ventilatory chemoreflexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Correct Answers on Knowledge of Kidney Transplant Options
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Recurrence gene profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Variation in Vital Capacity Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: decrease of total bilirubin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to definitive IBD-related treatment initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Connectivity between Ventral Striatum and Ventromedial Prefrontal Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: death from AAA after screening
Endpoint domain: Mortality/survival
Primary endpoint: over active bladder symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Experiencing Dose-limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Post-transplant diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of replies to peers' posts
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Content in replies to peers' posts
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Engagement with intervention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean and median values of TSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean and median values of FT4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Neuromotor-Neurocognitive development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of patients with adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects Who Develop Lower Respiratory Tract Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Irritation/Harshness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Appeal Assessed Using the Labeled Hedonic Scale (LHS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Appeal Assessed Using the Drug Effects Questionnaire (DEQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time required for epidural catheter insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean half life of drug in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean maximum concentration of drug in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean area under the curve of drug concentration in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical assessment of UE function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Intracortical Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CNS-ORR (Central Nervous System Objective Response Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ratio of maximum tolerated dose (MTD) of peanut protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event Rate of Stroke/Systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Event Rate of Major bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: All-Cause Mortality Rates
Endpoint domain: Mortality/survival
Primary endpoint: SARS-CoV-2 neutralizing antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: SARS-CoV-2 neutralizing antibody seroconversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hemagglutination Inhibition (HI) titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants consenting to inclusion and randomization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Compliance with the intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Disappearance of pulsatile tinnitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test performance measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers T1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers T2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of the masseter muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Masseter muscle stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number and Grade of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in QTcd
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to last time point (AUC0-t) of rupatadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of rupatadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal half-life (t1/2) of rupatadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescence detected by the investigational device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choroidal blood flow density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Length of time catheter remained in place
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cause of premature failure
Endpoint domain: Adverse events/effects
Primary endpoint: Number of dropout participants unable to use the VR-PMP simulator
Endpoint domain: Adverse events/effects
Primary endpoint: Paracetamol Peak Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paracetamol Area Under the Plasma Concentration Versus Time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioavailability (Frel) of the Maximum Observed Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioavailability (Frel) of the Area Under the Plasma Concentration-time Curve From Time Zero to 72h (AUC0-72h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioavailability (Frel) of the Area Under the Plasma Concentration-time Curve From Time Zero to the last quantifiable concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Density of Iodine in Lipiodol depositions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of establishment of exploitable tumor organoid lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Post-Birth Warning Signs Identified Per Participant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gut microbiome alpha and beta diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late lumen loss rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: One-year utility score of health related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Chewing performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swallowing performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Complete Remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Electrocortical EEG changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: N-back working memory changes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: β-hydroxybutyrylation of histone in human immune cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Periprocedural Serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Vascular patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Geometric Mean Titers (GMT) Ratio of Neutralizing Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Reported Solicited Local Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Serum 25-Hydroxyvitamin D [25(OH)D]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rate of new stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Rate of drug-related hemorrhagic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Juvenile Arthritis Biopsychosocial Questionnaire-JAB-Q-Patient
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Juvenile Arthritis Biopsychosocial Questionnaire-JAB-Q-Family
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Stair Climb Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 Seconds Sit to Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-Metre Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive accuracy of the computational model for myocardial blood flow (MBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse events (AE) and their incidence
Endpoint domain: Adverse events/effects
Primary endpoint: satisfaction of the common functions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: operation convenience assessment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: system stability assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in aortic stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of subjects with a complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of home monitoring
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in total score of the Parkinson's Disease Questionnaire 39-items scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Perceived pain level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Natural history of disease in patients with GI disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety and effectiveness of treatments
Endpoint domain: Adverse events/effects
Primary endpoint: Major bleeding event during DOAC therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Global Impressions scale-Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Child Yale Brown Obsessive Compulsive Scale- Pervasive Developmental Disorders (CYBOCS-PDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Share of enrollees employed in the fourth quarter after enrollment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Enrollee earnings in the fourth quarter after enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Share of enrollees that applied for SSDI or SSI during the 12 months after enrollment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-traumatic Stress Diagnostic Scale for the DSM-5 (PDS-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Center for Epidemiological Studies-Depression (CES-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: New child abuse/neglect welfare reports
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Daily Diary Pain NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in severity of tricuspid regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1hr pad weight test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in State-Anxiety Inventory-5 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence to the program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptability of video-discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Electroencephalography (EEG) signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Saint George's Solunum Anket
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self reported pain on movement from supine position to sitting position after 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite outcome of self reported morphine side effects occurring within 24 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Neonatal admission
Endpoint domain: Mortality/survival
Primary endpoint: Hemorrhoidal Disease Symptom Score (HDSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Short Health Scale HD (SHSHD)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of chronic pain after caesarean section
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Subjective information level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) I+II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PHQ-9 score ≥10
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sarcopenia screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of underlying EC and AEH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of underlying OC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Safety Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients who quit smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: recovering damaged organ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inhibiting inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: preventing the antibody depositing on antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants That Are Adherent to the Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Who Complete the Outcome Assessments Upon Program Completion
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants Who Report Adequate Acceptability of the Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in crisis events
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Compliance rate of prosthetic valve function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mental Health Treatment Initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in bone marrow doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in kidney doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Minimal Residual Disease (MRD)-negative response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fear response during acquisition indicated by elevated Galvanic Skin Response (GSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear response post-acquisition indicated by elevated GSR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Aesthetic Improvement Scale (GAIS) Rating
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cellulite Severity Scale (CSS) Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in subjective rating of appetite
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in serum concentration of large HDL particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent days absent
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Immobilization Comfort Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Benchmarking Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mechanical Detection Threshold (MDT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical Pain Sensitivity (MPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery Capital
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of clinically significant chromosomal aberrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological Capital
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence of Cataract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Skin Moisturization Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin Wrinkle Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Serum M protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of bone marrow plasma cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes